| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S17390 R72905 |
Madley-Dowd_SE (Phenytoin) (Controls exposed to LTG) (Mixed indications), 2024 | Intellectual disability - ICD-8/9/10 codes and/or ADHD medication prescription - Mean 5-20 years old (according groups) | during pregnancy (anytime or not specified) | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: Yes |
0.61 [0.19;1.96] excluded (control group) |
-/194 60/5,035 | - | 194 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S17391 R72911 |
Madley-Dowd_SE (Phenytoin) (Controls unexposed, general pop) (Mixed indications), 2024 | Intellectual disability - ICD-8/9/10 codes and/or ADHD medication prescription - Mean 5-20 years old (according groups) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed (general population or NOS) | Adjustment: Yes | 0.67 [0.22;2.10] | -/194 24,323/2,651,210 | - | 194 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S17392 R72917 |
Madley-Dowd_SE (Phenytoin) (Controls unexposed, sibling) (Mixed indications), 2024 | Intellectual disability - ICD-8/9/10 codes and/or ADHD medication prescription - Mean 5-20 years old (according groups) | during pregnancy (anytime or not specified) | population based cohort retrospective | sibling excluded | Adjustment: Yes |
0.53 [0.03;8.50] excluded (control group) |
-/- -/- | - | - |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S17268 R72289 |
Madley-Dowd_UK (Phenytoin) (Controls unexposed, general pop) (Mixed indications), 2024 | Intellectual disability - ICD10 codes - Median follow up 10.75 (7.82-13.62) years old | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: No | 5.04 [0.31;81.78] C | 0/46 1,119/514,066 | 1,119 | 46 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9266 R32135 |
Meador (Phenytoin), 2013 | IQ <70 (DAS) (at 6 years old) | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick | Adjustment: Yes | 1.86 [0.04;95.58] C | 0/40 0/74 | 0 | 40 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9269 R32147 |
Titze (Phenytoin) (Controls unexposed, disease free), 2008 | Learning disability (IQ<70) (German versions of the revised Wechsler Intelligence Scales for children and for adults) | during pregnancy (anytime or not specified) | prospective cohort | unexposed, disease free excluded | Adjustment: No Matched |
4.22 [0.08;223.98] C excluded (control group) |
0/12 0/49 | 0 | 12 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9270 R32148 |
Titze (Phenytoin) (Controls unexposed, sick), 2008 | Learning disability (IQ<70) (German versions of the revised Wechsler Intelligence Scales for children and for adults) | during pregnancy (anytime or not specified) | prospective cohort | unexposed, sick | Adjustment: No | 0.33 [0.01;9.07] C | 0/12 1/13 | 1 | 12 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 4 studies | 0.86 [0.33;2.25] | 1,120 | 292 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Phenytoin) (Controls unexposed, general pop) (Mixed indications; 2: Phenytoin) (Controls unexposed, general pop) (Mixed indications; 3: Phenytoin; 4: Phenytoin) (Controls unexposed, sick;
Asymetry test p-value = NaN (by Egger's regression)
not enought points
excluded 9269, 17390, 17392